Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206823) titled 'Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Primacy Immune Thrombocytopenia
Intervention:
Drug: Romiplostim N01
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: September 1, 2025
Target Sample Size: 30
Countries of Recruitment:
China
To know mor...